The estimated Net Worth of David R Brennan is at least $15.4 Milion dollars as of 1 November 2021. Mr. Brennan owns over 10,000 units of Alexion Pharmaceuticals stock worth over $14,806,778 and over the last 10 years he sold ALXN stock worth over $0. In addition, he makes $595,052 as Independent Chairman of the Board at Alexion Pharmaceuticals.
David has made over 3 trades of the Alexion Pharmaceuticals stock since 2014, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of ALXN stock worth $301,500 on 1 November 2021.
The largest trade he's ever made was buying 10,000 units of Alexion Pharmaceuticals stock on 1 November 2021 worth over $301,500. On average, David trades about 550 units every 105 days since 2014. As of 1 November 2021 he still owns at least 80,876 units of Alexion Pharmaceuticals stock.
You can see the complete history of Mr. Brennan stock trades at the bottom of the page.
David R. Brennan serves as Independent Chairman of the Board of the Company. Mr. Brennan served as Interim Chief Executive Officer of Alexion from December 11, 2016 to March 27, 2017. From 2006 to 2012, he was Chief Executive Officer and Executive Director of AstraZeneca PLC, one of the world’s largest pharmaceutical companies. Mr. Brennan worked for Astra Merck, Astra, and AstraZeneca in increasing roles of responsibility from 1992 through 2012, including as Executive Vice President of North America from 2001 to 2006, and as Senior Vice President of Commercialization and Portfolio Management from 1999 to 2001. Prior to the merger of Astra AB and Zeneca Plc, he served as Senior Vice President of Business Planning and Development of Astra Pharmaceuticals LP, the American subsidiary of Astra AB. Mr. Brennan began his career at Merck and Co. Inc., where he rose from Sales Representative in the U.S. Division to General Manager of Chibret International, a French subsidiary of Merck. He received a BA in business administration from Gettysburg College, where he is the Chairman of the Board of Trustees.
As the Independent Chairman of the Board of Alexion Pharmaceuticals, the total compensation of David Brennan at Alexion Pharmaceuticals is $595,052. There are 9 executives at Alexion Pharmaceuticals getting paid more, with Ludwig Hantson having the highest compensation of $18,948,000.
David Brennan is 66, he's been the Independent Chairman of the Board of Alexion Pharmaceuticals since 2017. There are 2 older and 16 younger executives at Alexion Pharmaceuticals. The oldest executive at Alexion Pharmaceuticals Inc. is John Mollen, 69, who is the Independent Director.
David's mailing address filed with the SEC is 700 US HIGHWAY 202/206, , BRIDGEWATER, NJ, 08807.
Over the last 21 years, insiders at Alexion Pharmaceuticals have traded over $451,742,532 worth of Alexion Pharmaceuticals stock and bought 2,576,434 units worth $277,855,180 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Leonard Bell oraz Paul A Friedman. On average, Alexion Pharmaceuticals executives and independent directors trade stock every 9 days with the average trade being worth of $3,460,578. The most recent stock trade was executed by Daniel Bazarko on 17 December 2020, trading 24,066 units of ALXN stock currently worth $2,816,685.
Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. As a leader in rare diseases for more than 25 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D) as well as the first and only approved Factor Xa inhibitor reversal agent. In addition, the company is developing several mid-to-late-stage therapies, including a copper-binding agent for Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases and an oral Factor D inhibitor as well as several early-stage therapies, including one for light chain (AL) amyloidosis, a second oral Factor D inhibitor and a third complement inhibitor. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology and acute care. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.
Alexion Pharmaceuticals executives and other stock owners filed with the SEC include: